VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
TFV rectal douche
Phase 2
Small molecule
N
National Institute of Allergy and Infectious Diseases (NIAID)
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Tenofovir
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Tenofovir
Phase 2
Completed
Clinical
Trials by Indication
[1]
Tenofovir
1 trial
A PHASE 2 CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR-BASED PREP EVALUATING EXTENDED SAFETY, ACCEPTABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS
Completed
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 2
·
NCT06560684
·
150 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for TFV rectal douche. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
TFV rectal douche compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for TFV rectal douche. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 2
[1]
Company
N
National Institute of Allergy and Infectious Diseases (NIAID)
Related News